BRISTOL MYERS SQUIBB CO Earnings Summary — Q1 2026
Bristol Myers Squibb Posts Solid Revenue Growth and Improved Operating Margin in Q1 FY2026
Key Takeaways
- Revenue grew 2.57% year-over-year to $11.49 billion, indicating a stabilization in the growth profile.
- GAAP Net Income recovered significantly to $2.68 billion following a highly volatile prior year marked by heavy R&D write-offs.
- Operating Income of $3.27 billion shows a return to normalized profitability after the acquisition-related losses in early 2024.
- Research & Development spending remains elevated at $2.74 billion (23.9% of revenue) as the company integrates recently acquired pipelines.
- The company continues to grapple with share count dilution, with basic shares outstanding rising 0.34% year-over-year.
- Revenue declined 8.1% on a sequential basis, though this followed a seasonally strong Q4 2025.
Management Guidance
Management remains focused on the integration of Karuna and RayzeBio acquisitions to offset looming patent cliffs for legacy blockbuster products like Eliquis and Opdivo.
Sentiment Shift
Improving
Earnings have stabilized significantly compared to the massive GAAP losses seen in 2024, showing a cleaner operating profile.
Outlook
The company is in a 'digest and deleverage' phase, focused on replacing aging revenue streams with new clinical launches while maintaining an investment-grade credit rating.
From the Annual Report (Key Quotes)
“BMY remains a cash-generating powerhouse in a transition phase, seeking to replace aging revenue streams with new pipeline launches.”
“Management has demonstrated a high appetite for risk-taking through transformational M&A to counter the 'Loss of Exclusivity' challenges.”
“The focus remains squarely on operational efficiency and hitting clinical milestones.”
Official Quarterly Documents
This summary is AI-generated from BRISTOL MYERS SQUIBB CO's latest quarterly filing and earnings call. For informational purposes only — not investment advice.